title: Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.
abstract: The effect of graft-versus-host disease (GVHD) on relapse incidence and survival has been analyzed in several studies, but previous studies included heterogeneous patients. Therefore, we analyzed the data of 2114 patients who received unmanipulated bone marrow graft from an HLA-identical sibling donor with a GVHD prophylaxis using cyclosporin A and methotrexate. Among the 1843 patients who survived without relapse at 60 days after transplantation, 435 (24%) developed grade II-IV acute GVHD. Among the 1566 patients who survived without relapse at 150 days after transplantation, 705 (47%) developed chronic GVHD. The incidence of relapse was significantly lower in patients who developed acute or chronic GVHD, but disease-free survival (DFS) was significantly inferior in patients who developed acute GVHD. A benefit of 'mild' GVHD was only seen in high-risk patients who developed grade I acute GVHD. The strongest association between GVHD and a decreased incidence of relapse was observed in patients with standard-risk acute myelogenous leukemia/myelodysplastic syndrome. In conclusion, the therapeutic window between decreased relapse and increased transplant-related mortality due to the development of GVHD appeared to be very narrow.
authors.affiliation: Department of Cell Therapy and Transplantation Medicine, University of Tokyo Hospital, Japan. ycanda-tky@umin.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Kanda
authors.forename: K
authors.initials: K
authors.lastname: Izutsu
authors.forename: H
authors.initials: H
authors.lastname: Hirai
authors.forename: H
authors.initials: H
authors.lastname: Sakamaki
authors.forename: T
authors.initials: T
authors.lastname: Iseki
authors.forename: Y
authors.initials: Y
authors.lastname: Kodera
authors.forename: S
authors.initials: S
authors.lastname: Okamoto
authors.forename: H
authors.initials: H
authors.lastname: Mitsui
authors.forename: K
authors.initials: K
authors.lastname: Iwato
authors.forename: N
authors.initials: N
authors.lastname: Hirabayashi
authors.forename: T
authors.initials: T
authors.lastname: Furukawa
authors.forename: A
authors.initials: A
authors.lastname: Maruta
authors.forename: M
authors.initials: M
authors.lastname: Kasai
authors.forename: Y
authors.initials: Y
authors.lastname: Atsuta
authors.forename: N
authors.initials: N
authors.lastname: Hamajima
authors.forename: A
authors.initials: A
authors.lastname: Hiraoka
authors.forename: K
authors.initials: K
authors.lastname: Kawa
mesh_terms: D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000401:mortality; D016572:Cyclosporine / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications* / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D012008:Recurrence
chemical_list: D016572:Cyclosporine; D008727:Methotrexate